- Conditions
- Colorectal Cancer
- Interventions
- celecoxib, gene expression analysis, protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, mass spectrometry, biopsy, neoadjuvant therapy, therapeutic conventional surgery
- Drug · Genetic · Other + 1 more
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2008
- U.S. locations
- 2
- States / cities
- Nashville, Tennessee
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 128
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Bacterial Infections, Bacterial Infections and Mycoses, Infections, Vaginitis, Vaginal Diseases, Genital Diseases, Female, Female Urogenital Diseases, Urogenital Disease, Candidiasis, Mycoses, Vulvovaginitis, Vulvar Diseases, Vaginosis, Bacterial
- Interventions
- Nanopath Vaginitis Assay, BD Max™ Vaginal Panel, Cepheid Xpert® Xpress MVP, Hologic Aptima® BV Assay, Yeast Culture
- Diagnostic Test
- Lead sponsor
- Nanopath, Inc
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 2
- States / cities
- North Miami, Florida • New Orleans, Louisiana
- Conditions
- Methadone Toxicity, Methadone Overdose, Pain, Chronic, Drug Metabolism, Poor, CYP2D6-Related, Metabolism Medication Toxicity
- Interventions
- Measurement of Methadone in the Interstitial Fluid (ISF) before and after prescribed dose taken ex vivo, Measurement of Methadone in the Interstitial Fluid before and after prescribed dose taken in vivo, ISF Extraction Device 2
- Diagnostic Test · Drug · Device
- Lead sponsor
- Cari Health Inc.
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Lemon Grove, California
- Conditions
- Childhood Cancer
- Interventions
- One-time blood draw, Evaluation of CpG methylation, Metabolomic analysis
- Other
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Glioma
- Interventions
- Non-Interventional Study
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 285 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Early Stage Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II
- Interventions
- Intra-operative Magnetic Resonance Imaging (MRI), Mass Spectrometer Analysis of Tissue Sample
- Procedure · Other
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years to 75 Years · Female only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Colorectal Cancer
- Interventions
- celecoxib, fluorouracil, conventional surgery, radiation therapy, tumor biopsy, laboratory biomarker analysis
- Drug · Procedure · Radiation + 1 more
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2008
- U.S. locations
- 2
- States / cities
- Nashville, Tennessee
- Conditions
- Breast Cancer
- Interventions
- gene expression analysis, mutation analysis, proteomic profiling, reverse transcriptase-polymerase chain reaction, fluorescent antibody technique, immunohistochemistry staining method, laboratory biomarker analysis, liquid chromatography, mass spectrometry, medical chart review, quality-of-life assessment
- Genetic · Other · Procedure
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 20 Years and older · Female only
- Enrollment
- 563 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2019
- U.S. locations
- 3
- States / cities
- Beverly Hills, California • Duarte, California • Pasadena, California
- Conditions
- Untreated Adult Acute Myeloid Leukemia
- Interventions
- midostaurin, azacitidine, bone marrow aspiration, mutation analysis, Pharmacokinetic study
- Drug · Other
- Lead sponsor
- Brenda Cooper, MD
- Other
- Eligibility
- Not listed
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2017
- U.S. locations
- 2
- States / cities
- Cleveland, Ohio • Morgantown, West Virginia
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Peripheral T-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Multiple Myeloma, Relapsing Chronic Myelogenous Leukemia, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Stage III Chronic Lymphocytic Leukemia, Testicular Lymphoma, Waldenström Macroglobulinemia
- Interventions
- fludarabine phosphate, methoxyamine, laboratory biomarker analysis, pharmacological study, western blotting, mass spectrometry, DNA analysis
- Drug · Other · Genetic
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Renal Cell Carcinoma, Clear-cell Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Kidney Cancer
- Interventions
- Proteomic profiling of urinary EVs, Blood sample collection
- Other · Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- Not listed
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Breast Cancer
- Interventions
- U-13C-glucose
- Drug
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 2
- States / cities
- New Brunswick, New Jersey
- Conditions
- Rosacea, Erythematotelangiectatic
- Interventions
- Metronidazole cream, Cetaphil moisturizer, CeraVe moisturizer, Eucerin Healing Lotion moisturizer, Aveeno Calm and Restore Oat Gel moisturizer
- Drug · Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Lung Cancer
- Interventions
- proteomic profiling, surface-enhanced laser desorption/ionization-time of flight mass spectrometry, biopsy, surgery
- Genetic · Other · Procedure
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2011
- U.S. locations
- 72
- States / cities
- Birmingham, Alabama • Concord, California • Duarte, California + 53 more
- Conditions
- Brain and Central Nervous System Tumors, Metastatic Cancer
- Interventions
- temozolomide, laboratory biomarker analysis, liquid chromatography, mass spectrometry, pharmacological study, conventional surgery, stereotactic radiosurgery
- Drug · Other · Procedure + 1 more
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 2
- States / cities
- Duarte, California • Pasadena, California
- Conditions
- Pancreatic Cancer
- Interventions
- protein expression analysis, laboratory biomarker analysis, mass spectrometry, surface-enhanced laser desorption/ionization-time of flight mass spectrometry
- Genetic · Other
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Cardiac Sarcoidosis, Sarcoidosis of the Heart, Sarcoidosis With Myocarditis, Sarcoidosis, Cardiac
- Interventions
- Exosome Analysis
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 115 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- HIV Risk
- Interventions
- urine-based self-test, urine-based clinic test
- Diagnostic Test
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Gastric Antral Vascular Ectasia, Cirrhosis, Chronic Kidney Disease
- Interventions
- Gastric Emptying Breath Test
- Diagnostic Test
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- temozolomide, veliparib, DNA methylation analysis, gene expression analysis, mutation analysis, proteomic profiling, high performance liquid chromatography, immunoenzyme technique, laboratory biomarker analysis, mass spectrometry, pharmacogenomic studies, pharmacological study, adjuvant therapy, radiation therapy
- Drug · Genetic · Other + 2 more
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • San Francisco, California • Atlanta, Georgia + 8 more
- Conditions
- Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia
- Interventions
- entinostat, imatinib mesylate, laboratory biomarker analysis, pharmacological study, western blotting, immunohistochemistry staining method, flow cytometry, polymerase chain reaction, high performance liquid chromatography, mass spectrometry
- Drug · Other · Genetic
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Environmental Exposure
- Interventions
- [14C]-benzo[a]pyrene
- Drug
- Lead sponsor
- Oregon State University
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Corvallis, Oregon
- Conditions
- Adnexal Mass, Ovarian Cancer, Pelvic Mass
- Interventions
- Not listed
- Lead sponsor
- Venn Biosciences Corporation
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,025 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 10
- States / cities
- Los Angeles, California • San Jose, California • Sunnyvale, California + 7 more
- Conditions
- Prostate Cancer
- Interventions
- proteomic profiling, immunological diagnostic method, laboratory biomarker analysis, mass spectrometry, biopsy, ultrasound imaging
- Genetic · Other · Procedure
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years to 120 Years · Male only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 2
- States / cities
- Menlo Park, California • Winston-Salem, North Carolina